Medical management of Crohn's disease

Bibliography

• Best WR, Becktel JM, Singleton JW, Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44
   PubMed Web of Science ®Google Scholar
• Winship DH, Summers RW, Singleton JW, National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979;77:829-42
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Panes J, European Crohn's and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010;4:7-27
   PubMed Web of Science ®Google Scholar
• Orlando A, Armuzzi A, Papi C, The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011;43:1-20
   PubMedGoogle Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980;1:514
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Sandborn WJ, Correlation between the Crohn's disease activity and Harvey–Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010;4:357-63
   Google Scholar
• Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27-32
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Reinisch W, European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010;4:63-101
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665-72
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002;359:1541-9
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D'Haens GR, Van Assche G, Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic crohn's disease – first results of the extend trial. DDW 2009;751e
   Google Scholar
• Frøslie KF, Jahnsen J, Moum BA, Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22
   PubMed Web of Science ®Google Scholar
• Irvine EJ, Feagan B, Rochon J, Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96
   PubMed Web of Science ®Google Scholar
• Sostegni R, Daperno M, Scaglione N, Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003;17(Suppl 2):11-17
   PubMed Web of Science ®Google Scholar
• Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol 1988;83:497-503
   PubMed Web of Science ®Google Scholar
• Baron JH, Connel AM, Lennard-Jones JE, Sulphasalzine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962;1:1094-6
   PubMed Web of Science ®Google Scholar
• Misiewicz J, Lennard-Jones JE, Connell AM, Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1:185-8
   Web of Science ®Google Scholar
• Summers RW, Switz DM, Sessions JT Jr, National Cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979;77:847-69
   PubMed Web of Science ®Google Scholar
• Malchow H, Ewe K, Brandes JW, European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66
   PubMed Web of Science ®Google Scholar
• Azad Kahn AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5
   PubMedGoogle Scholar
• Van Hees PAM, Bakker JH, Van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: study to determine the active therapeutic moiety of sulphasalazine. Gut 1980;21:632-5
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Stromberg U. Oral pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-88
   PubMed Web of Science ®Google Scholar
• Singleton JW, Hanauer SB, Gitnick GL, Mesalamine capsules for the treatment of active Crohn's disease: results of a 16 week trial. Gastroenterology 1993;104:1293-301
   PubMed Web of Science ®Google Scholar
• Nordic Research, Inc. Clinical research report: efficacy and safety of oral Pentasa in the treatment of active Crohn's disease. 1991
   Google Scholar
• Hoechst Marion Roussel, Inc. Clinical study report: efficacy and safety of oral Pentasa in the treatment of active Crohn's disease. 1997
   Google Scholar
• Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994;107:632-3
   PubMedGoogle Scholar
• Thomsen OO, Cortot A, Jewell D, A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med 1998;339:370-4
   PubMed Web of Science ®Google Scholar
• Tromm A, Bunganic I, Tomsova E, Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology 2011;140:425-34
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO, The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4:28-62
   PubMed Web of Science ®Google Scholar
• Ford AC, Kane SV, Khan KJ, Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:617-29
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther 2006;28:1983-8
   PubMed Web of Science ®Google Scholar
• Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000;95:725-9
   PubMed Web of Science ®Google Scholar
• Selby W, Pavli P, Crotty B, Two year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007;132:2313-19
   PubMed Web of Science ®Google Scholar
• Prantera C, Lochs H, Campieri M, Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23:1117-25
   PubMed Web of Science ®Google Scholar
• Khan KJ, Ullman TA, Ford AC, Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:661-73
   PubMed Web of Science ®Google Scholar
• Fahey JV, Guyer PM, Munck A. Mechanisms of anti-inflammatory actions of glucocorticoids. Advances in inflammatory research. Raven Press; New York: 1981
   Google Scholar
• Benchimol EI, Seow CH, Steinhart AH, Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008;2:CD006792
   PubMedGoogle Scholar
• Singleton JW, Law DH, Kelley ML Jr, National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979;77:870-82
   PubMed Web of Science ®Google Scholar
• Brattsand R. Overview of newer glucocorticoid preparations for inflammatory bowel disease. Can J Gastroenterol 1990;4:407-14
   Google Scholar
• Thomsen OO, Cortot A, Jewell D, A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide–Mesalamine Study Group. N Engl J Med 1998;339:370-4
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Lofberg R, Malchow H, A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5
   PubMed Web of Science ®Google Scholar
• Gross V, Andus T, Caesar I, Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996;8:905-9
   PubMed Web of Science ®Google Scholar
• Campieri M, Ferguson A, Doe W, Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997;41:209-14
   PubMed Web of Science ®Google Scholar
• Bar-Meier S, Chowers Y, Lavy A, Budesonide versus prednisone in the treatment of active Crohn's disease. Gastroenterology 1998;115:835-40
   PubMedGoogle Scholar
• Greenberg GR, Feagan BG, Martin F, Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836-41
   PubMed Web of Science ®Google Scholar
• Tremaine WJ, Hanauer SB, Katz S, Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748-54
   PubMed Web of Science ®Google Scholar
• D'Haens G, Verstraete A, Cheyns K, Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther 1998;12:419-24
   PubMed Web of Science ®Google Scholar
• Escher JC. European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004;16:47-54
   PubMed Web of Science ®Google Scholar
• Levine A, Weizman Z, Broide E, A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003;36:248-52
   PubMed Web of Science ®Google Scholar
• Tursi A, Giorgetti GM, Brandimarte G, Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study. Med Sci Monit 2006;12:PI29-32
   PubMed Web of Science ®Google Scholar
• Van Ierssel AJ, Van der Sluys Veer A, Verspaget HW, Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn's disease. Aliment Pharmacol Ther 1995;9:173-8
   PubMed Web of Science ®Google Scholar
• Seow CH, Benchimol EI, Griffiths AM, Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008;3:CD000296
   Google Scholar
• Munkholm P, Langholz E, Davidsen M, Frequency of glucocorticoid resistance and dependency in Crohn's disease Gut 1994;35:360-2
   Google Scholar
• Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009;4: CD000545
   Google Scholar
• Present DH, Korelitz BI, Wisch N, Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7
   PubMed Web of Science ®Google Scholar
• Khan KJ, Dubinsky MC, Ford AC, Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:630-42
   PubMed Web of Science ®Google Scholar
• Hindorf U, Johansson M, Eriksson A, Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009;29:654-61
   PubMed Web of Science ®Google Scholar
• Arora S, Katkov W, Cooley J, Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724-9
   PubMed Web of Science ®Google Scholar
• Mate-Jimenez J, Hermida C, Cantero-Perona J, 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12:1227-33
   PubMed Web of Science ®Google Scholar
• Oren R, Moshkowitz M, Odes S, Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997;92:2203-9
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Bollani S, Manzionna G, Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003;35:619-27
   PubMedGoogle Scholar
• Feagan BG, Rochon J, Fedorak RN, Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7
   PubMed Web of Science ®Google Scholar
• Loper-Cubero SO, Sullivan K, MacDonald G. Course of Crohn's disease after allogenic marrow transplantation. Gastroenterology 1998;114:433-40
   PubMedGoogle Scholar
• Cassinotti A, Annaloro C, Ardizzone S, Autologous haematopoietic stem cell trasplantation without CD34+ cell selection in refractory Crohn's disease. Gut 2008;57:211-17
   PubMed Web of Science ®Google Scholar
• Neurath MF, Wanitschke R, Peters M, Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999;44:625-8
   PubMed Web of Science ®Google Scholar
• Palaniappan S, Ford AC, Greer D, Mycophenolate mofetil therapy for refractory inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1488-92
   PubMedGoogle Scholar
• Stallmach A, Wittig BM, Moser C, Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut 2003;52:377-82
   PubMed Web of Science ®Google Scholar
• Srinivasan R, Akobeng AK. Thalidomide and thalidomide analogues for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009;2:CD007350
   Google Scholar
• Zheng CF, Xu JH, Huang Y, Treatment of pediatric refractory Crohn's disease with thalidomide. World J Gastroenterol 2011;17:1286-91
   PubMed Web of Science ®Google Scholar
• Summers RW, Elliott DE, Urban JF Jr, Trichuris suis therapy in Crohn's disease. Gut 2005;54:87-90
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn VJ, Rutgeers P, Human anti-tumor necrosis factor monocolonal antibodies (adalimumab) in Crohn's disease: the classic I trial. Gastroenterology 2006;130:322-33
   Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N, Efficacy and safety of tumor necrosis factor antagonistis in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59
   PubMed Web of Science ®Google Scholar
• Lemann M, Mary JY, Duclos B, Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054-61
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, Infliximab, azathioprine or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
   PubMed Web of Science ®Google Scholar
• Lofberg R, Louis E, Reinisch W, Adalimumab effectiveness in TNF antagonist-naive patients and in infliximab non responders with Crohn's disease: results from the Care Study. Am J Gastroenterol 2008;103(Suppl 1):S418
   Google Scholar
• Sandborn WJ, Rutgeers P, Enns R, Adalimumab induction therapy for Crohn's disease previously treated with infiximab: a randomized trial. Ann Intern Med 2007;146:829-38
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
   PubMed Web of Science ®Google Scholar
• Colombel JF, Hebuterne X. Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC clinical trial [abstract]. Am J Gastroenterol 2008;103:A1107
   Google Scholar
• Sandborn WJ, Vermeire S, D'Haens G, Welcome: a randomized, double-blind, controlled trial comparing certolizumab pegol 400 mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate to severe Crohn's Disease with secondary failure to infliximab. Gastroenterology 2009;136(Suppl 1):A47
   Google Scholar
• Schnitzler F, Fidder H, Ferrante M, Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301
   PubMed Web of Science ®Google Scholar
• Cottone M, Kohn A, Daperno M, Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:30-5
   PubMed Web of Science ®Google Scholar
• D'Haens G, Baert F, van Assche G, Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7
   PubMed Web of Science ®Google Scholar
• Schreiber S, Reinisch W, Colombel JF. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology 2007;132(Suppl 2):A985
   Google Scholar
• Beaugerie L, Seksik P, Nion-Larmurier I, Predictors of Crohn's disease. Gastroenterology 2006;130:650-6
   PubMed Web of Science ®Google Scholar
• Korzenick JR, Dieckgraefe BK, Valentine JF, Salmograstin for active Crohn's disease. N Engl J Med 2005;352:2193-201
   PubMed Web of Science ®Google Scholar
• Feagan BG, Anderson F, Radford-Smith GL, Efficacy and safety of salmograstin in moderate to severe Crohn's disease: results of NOVEL 4 phase multicenter study. Gastroenterology 2007;132(Suppl 2):A103
   PubMedGoogle Scholar
• Valentine JF, Fedorak RN, Feagan B, Steroid sparing properties of sarmograstin in patients with corticosteroid dependent Crohn's disease: a randomized double blind placebo controlled phase 3 study. Gut 2009;58:1354-62
   PubMed Web of Science ®Google Scholar
• Van Deventer SJH, Elson C, Fedorak R. Multiple doses of intravenous interleukin 10 in steroid refractory Crohn's disease. Gastroenterology 1997;113:383-9
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Malchow H, Interleukin 10 in the prevention of postoperative recurrence. Gut 2001;49:42-6
   PubMed Web of Science ®Google Scholar
• Ito H, Takazoe M, Fukuda Y, A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-96
   PubMed Web of Science ®Google Scholar
• Burakoff R, Barish CF, Riff D, A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 2006;12:558-65
   PubMed Web of Science ®Google Scholar
• Mannon PJ, Fuss IJ, Mayer L, Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-79
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate to severe Crohn's disease. Gastroenterology 2008;135:1130-41
   PubMed Web of Science ®Google Scholar
• Reinisch W, Hommes DW, Van Assche G, A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006;55:1138-44
   PubMed Web of Science ®Google Scholar
• Hommes DW, Mikhajlova TL, Stoinov S, Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55:1131-7
   PubMed Web of Science ®Google Scholar
• Reinisch W, de Villiers W, Bene L, Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010;16:233-42
   PubMed Web of Science ®Google Scholar
• Kasran A, Boon A, Wortel H. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005;22:1111-22
   Google Scholar
• Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev 2009;4:CD007277
   Google Scholar
• Ghosh S, Goldin E, Gordon FH, Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, Natalizumab induction and maintenance therapy for Crohn's disease. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. N Engl J Med 2005;353:1912-25
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83
   PubMed Web of Science ®Google Scholar
• Sands BE, Kozarek R, Spainhour J, Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007;13:2-11
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114:1133-42
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Barish C, Goff J, Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 2002;16:1761-70
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Chey WY, Goff J, Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-6
   PubMed Web of Science ®Google Scholar
• Yacyshyn B, Chey WY, Wedel MK, A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of a subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007;5:215-20
   PubMed Web of Science ®Google Scholar
• Keshav S, Wolf D, Katz S, CCX282-B, an orally active inhibitor of chemokine receptor CCR9, in a randomized, double-blind, placebo-controlled phase 2 study in moderate to severe Crohn's disease. Gut 2006;A22:OP-G-93
   Google Scholar
• Hommes D, Van de blink B, Plasse T, Inhibition of stress activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002;122:7-14
   PubMed Web of Science ®Google Scholar
• Schreiber S, Feagan B, D'Haens G, Oral p38 mitogen activated protein kinase inibition with BIRB 796 for active Crohn's disease:a randomized double blind placebo controlled trial. Clin Gastroenterol Hepatol 2006;4:325-34
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE. Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial. Gut 1977;18:69-72
   PubMedGoogle Scholar
• Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically induced remission in Crohn's disease [review]. Cochrane Libr 2009;4
   Google Scholar
• Mahmud N, Kamm MA, Dupas JL, Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut 2001;49:552-6
   PubMed Web of Science ®Google Scholar
• Patel H, Barr Jeejeebhoy. Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 2009;23:170-6
   PubMed Web of Science ®Google Scholar
• Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the committee on safety of medicines. Gut 2002;51:536-9
   PubMed Web of Science ®Google Scholar
• Chakraborty TK, Bhatia D, Heading RC, Salicylate induced exacerbation of ulcerative colitis. Gut 1987;28:613-15
   PubMed Web of Science ®Google Scholar
• Feller M, Huwiler K, Schoepfer A, Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 2010;50:473-80
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Hiele M, Geboes K, Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Vermeire S, Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, doubleblind, placebo-controlled trial. Gastroenterology 2005;128:856-61
   PubMed Web of Science ®Google Scholar
• Steinhart AH, Ewe K, Griffiths AM, Traditional corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;4:CD006792
   Google Scholar
• Brignola C, De Simone G, Belloli C, Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994;8:465-8
   PubMedGoogle Scholar
• Benchimol EI, Seow CH, Otley AR, Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;1:CD002913
   Google Scholar
• Prefontaine E, Sutherland LR, Macdonald JK, Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;1:CD000067
   PubMed Web of Science ®Google Scholar
• Lemann M, Mary JY, Colombel J-F, A randomized, double blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812-18
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25
   PubMed Web of Science ®Google Scholar
• Bebb JR, Logan RP. Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma? Aliment Pharmacol Ther 2001;15:1843-9
   PubMedGoogle Scholar
• Feagan BG, Fedorak RN, Irvine EJ, A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32
   PubMed Web of Science ®Google Scholar
• Oren R, Moshkowitz M, Odes S, Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997;92:2203-9
   PubMed Web of Science ®Google Scholar
• Feagan BG, McDonald JWD, Panaccione R, A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Presented at Digestive Disease Week, 17 – 22 May 2008, San Diego, CA, USA
   Google Scholar
• Mackey AC, Green L, Liang LC, Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7
   PubMed Web of Science ®Google Scholar
• Shale MS, Kanfer E, Panaccione R, Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008;57:1639-41
   PubMed Web of Science ®Google Scholar
• Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk 2010;10:144-8
   PubMed Web of Science ®Google Scholar
• Panaccione R, Colombel GF, Sandborn WJ, Adalimumab sustains clinical remission and overall clinical benefit after 2 years therapy for Crohn's disease. Aliment Pharmacol Ther 2010;31:1296-309
   PubMed Web of Science ®Google Scholar
• Fidder H, Schnitzler F, Ferrante M, Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre color study. Gut 2009;58:501-8
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500
   PubMed Web of Science ®Google Scholar
• Reinisch W, Panes J, Lemann M, A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008;103:2284-92
   PubMed Web of Science ®Google Scholar
• Pena-Rossi C, Schreiber S, Golubovic G, Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis. Aliment Pharmacol Ther 2008;28:758-6
   PubMed Web of Science ®Google Scholar
• Renna S, Camma C, Modesto I, M. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2008;135:1500-9
   PubMed Web of Science ®Google Scholar
• Cottone M, Rosselli M, Orlando A, Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994;106:643-8
   PubMed Web of Science ®Google Scholar
• Reese GE, Nanidis T, Borysiewicz C, The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008;23:1213-21
   PubMed Web of Science ®Google Scholar
• Simillis C, Yamamoto T, Reese GE, A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease. Am J Gastroenterol 2008;103:196-205
   PubMed Web of Science ®Google Scholar
• Greenstein AJ, Lachman P, Sachar DB, Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988;29:588-92
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol 2005;11:3971-9
   PubMed Web of Science ®Google Scholar
• Doherty G, Bennett G, Patil S, Intervention for prevention of postoperative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009
   PubMedGoogle Scholar
• Lochs H, Mayer M, Fleig WE, Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000;118:264-73
   PubMed Web of Science ®Google Scholar
• Cottone M, Camma C. Mesalamine and relapse prevention in Crohn's disease. Gastroenterology 2000;119:597
   PubMed Web of Science ®Google Scholar
• D'Haens GR, Vermeire S, Van Assche G, Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008;135:1123-9
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Korelitz BI, Rutgeerts P, Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127:723-9
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, Ardizzone S, Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009;104:2089-96
   PubMed Web of Science ®Google Scholar
• Reinisch W, Angelberger S, Petritsch W, Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010;59:752-9
   PubMed Web of Science ®Google Scholar
• Van Gossum A, Dewit O, Louis E, Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 2007;13:135-42
   PubMed Web of Science ®Google Scholar
• Marteau P, Lemann M, Seksik P, Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006;55:842-7
   PubMed Web of Science ®Google Scholar
• Prantera C, Scribano ML, Falasco G, Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-9
   PubMed Web of Science ®Google Scholar
• Regueiro M, Schraut W, Baidoo L, Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009;136:441-50
   PubMed Web of Science ®Google Scholar
• Sorrentino D, Terrosu G, Avellini C, Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007;167:1804-7
   PubMedGoogle Scholar
• Haggett PJ, Moore NR, Shearman JD, Pelvic and perineal complications of Crohn's disease: assessment using magnetic resonance imaging. Gut 1995;36:407-10
   PubMedGoogle Scholar
• Skalej M, Makowiec F, Weinlich M, Magnetic resonance imaging in perianal Crohn's disease. Dtsch Med Wochenschr 1993;118:1791-6
   PubMedGoogle Scholar
• Koelbel G, Schmiedl U, Majer MC, Diagnosis of fistulae and sinus tracts in patients with Crohn disease: value of MR imaging. AJR Am J Roentgenol 1989;152:999-1003
   PubMed Web of Science ®Google Scholar
• Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002;45:39-46
   PubMed Web of Science ®Google Scholar
• Sloots CE, Felt-Bersma RJ, Poen AC, Assessment and classification of fistula-in-ano in patients with Crohn's disease by hydrogen peroxide enhanced transanal ultrasound. Int J Colorectal Dis 2001;16:292-7
   PubMedGoogle Scholar
• Orsoni P, Barthet M, Portie F, Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn's disease. Br J Surg 1999;86:360-4
   PubMedGoogle Scholar
• Parks AG, Gordon PH, Hardcastle J. A classification of fistula-in-ano. Br J Surg 1976;63:1-12
   PubMed Web of Science ®Google Scholar
• Bell SJ, Williams AB, Wiesel P, The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther 2003;17:1145-51
   PubMed Web of Science ®Google Scholar
• Bernstein LH, Frank MS, Brandt LJ, Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79:357-65
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Bernstein LH, Boley SJ, Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;83:383-7
   PubMed Web of Science ®Google Scholar
• Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984;79:533-40
   PubMed Web of Science ®Google Scholar
• Thia KT, Mahadevan U, Feagan BG, Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009;15:17-24
   PubMed Web of Science ®Google Scholar
• Pearson DC, May GR, Fick GH, Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-42
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
   PubMed Web of Science ®Google Scholar
• Gaertner WB, Decanini A, Meligren A, Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum 2007;50:1754-60
   PubMed Web of Science ®Google Scholar
• Hyder SA, Travis SP, Jewell DP, Fisulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006;49:1837-41
   PubMed Web of Science ®Google Scholar
• Topstad DR, Panaccion R, Heine JA, Combined seton placement, infliximab infusion, and maintenance immunosuppressives improving healing rate in fistulising anorectal Crohn's disease. A single center experience. Dis Colon Rectum 2003;46:577-83
   PubMed Web of Science ®Google Scholar
• Van der Hagen SJ, Baeten CG, Soeters PB, Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report. Dis Colon Rectum 2005;48:758-67
   PubMedGoogle Scholar
• Lichtenstein GR, Diamond RH, Wagner CL, Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009;30:210-26
   PubMed Web of Science ®Google Scholar
• Sokol H, Seksik P, Carrat F, Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363-8
   PubMed Web of Science ®Google Scholar
• Moss AC, Kim KJ, Fernandez-Becker N, Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci 2010;55:1413-20
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8
   PubMed Web of Science ®Google Scholar
• D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's ileo colitis with azathioprine. Gastrointest Endosc 1999;50:667-71
   PubMed Web of Science ®Google Scholar
• D'Haens GR, Noman M, Baert F, Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology 2002;122:776(A)
   Google Scholar
• Rutgeerts P, Diamond RH, Bala M, Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42
   PubMed Web of Science ®Google Scholar